The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx.
Telix is Regeneron’s entry ticket into the radiopharma game, helping to better round out the company’s cancer portfolio, according to Truist Securities.
Replimune’s CEO Sushil Patel has already warned that the biotech will need to cut staff and substantially scale back its U.S. manufacturing operations.
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
The Internal Revenue Service and the Treasury released final regulations on the new tax deduction for tipped employees under the One Big Beautiful Bill Act.
Plus, Oracle premieres Fusion Agentic Applications; Suralink launches Financial Statement Tie Out solution; and other accounting tech news and updates.